OncoMatch/Clinical Trials/NCT05007873
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
Is NCT05007873 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Dasatinib and Decitabine and Cedazuridine for chronic phase chronic myelogenous leukemia.
Treatment: Dasatinib · Decitabine and Cedazuridine — This phase II trial studies the effect of ASTX727 and dasatinib in treating patients with newly diagnosed Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia in chronic phase. Philadelphia chromosome positive and BCR-ABL positive are types of genetic mutations (changes). Chemotherapy drugs, such as ASTX727, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. ASTX727 and dasatinib may help to control Philadelphia chromosome-positive chronic myeloid leukemia or BCR-ABL positive chronic myeloid leukemia in chronic phase.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Myeloid Leukemia
Biomarker criteria
Required: BCR-ABL1 fusion
BCR-ABL positive CML
Required: ABL1 fusion
Philadelphia chromosome (Ph)-positive
Disease stage
Required: Stage EARLY CHRONIC PHASE
Excluded: Stage LATE CHRONIC PHASE, ACCELERATED PHASE, BLAST PHASE
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: tyrosine kinase inhibitor
Exception: < 1 month (30 days) of prior FDA approved TKI allowed
< 1 month (30 days) of prior Food and Drug Administration (FDA) approved tyrosine kinase inhibitor (TKI)
Cannot have received: cytarabine (cytarabine)
Exception: 1 to 2 doses allowed
1 to 2 doses of cytarabine
Cannot have received: hydroxyurea (hydroxyurea)
Except for hydroxyurea
Lab requirements
Kidney function
creatinine clearance ≥ 30ml/min calculated using modified crokcroft-gault
Liver function
total bilirubin <1.5x uln (unless secondary to gilbert's disease, in which case should be < 2.5x uln), sgpt <3x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify